Abstract 9772: Paroxysmal Atrial Fibrillation Among Pulmonary Embolism Patients; Insight From the 2019 National Inpatient Sample

Circulation, Volume 146, Issue Suppl_1, Page A9772-A9772, November 8, 2022. Introduction:Various factors can trigger events of Pulmonary Embolism(PE). Several studies have linked cardiac arrhythmias such as Paroxysmal Atrial Fibrillation (PAF) with a higher risk of multiple cardiovascular and pulmonary complications. As there is a paucity of data on the risk factors for an event of PAF among PE patients and the factors contributing to death, we conducted a retrospective analysis using the 2019 National Inpatient Sample(NIS).Methods:Our study focused on finding patients with a principal diagnosis of Pulmonary Embolism and a diagnosis of Paroxysmal Atrial Fibrillation. A multivariable regression model evaluated several risk factors for PAF incidence among PE patients and their possible mortality risks.Results:A total of 188,850 cases of PE were observed in our study, including 9,960 (5.3%) cases of PAF. Hyperlipidemia (aOR 1.348, 95% CI 1.290-1.409, p

Leggi
Ottobre 2022

Abstract 14128: Impact of Sarcoidosis in Patients Undergoing Aortic Valve Replacement: Insight From National Readmission Database 2016-2019

Circulation, Volume 146, Issue Suppl_1, Page A14128-A14128, November 8, 2022. Introduction:Limited data exist on the in-hospital and readmission outcomes in sarcoidosis patients after surgical or transcatheter aortic valve replacement (SAVR/TAVR).Hypothesis:Sarcoidosis can lead to cardiac conduction abnormalities and cardiomyopathy which can lead to poor outcomes after aortic valve intervention (AVI). We hypothesize that SAVR/TAVR in sarcoidosis patients has the worst outcomes.Methods:The NRD was queried for all sarcoidosis patients who underwent SAVR/TAVR from 2016-2019. Our outcomes of interest were in-hospital mortality, in-hospital complications, and 30-day readmissions for heart failure and pacemaker implantation. Clinical outcomes were modeled using logistic regression for binary outcomes and linear regression for continuous outcomes.Results:We identified a total of 507,441 SAVR/TAVR hospitalizations of which 1429 were of sarcoidosis patients. Patients with sarcoidosis were younger (mean age 70.1 years vs 72.4 years) and had more women (48.3% vs 38.2%, p

Leggi
Ottobre 2022

Abstract 14273: Obesity Paradox and Its Impact on Heart Failure With Preserved Ejection Fraction (HFpEF) in Geriatric Patients: A 2019 National Inpatient Analysis

Circulation, Volume 146, Issue Suppl_1, Page A14273-A14273, November 8, 2022. Introduction:Several studies have shown obesity to be inversely associated with mortality, the so-called obesity paradox. Although being a major cardiovascular risk factor, patients with morbid obesity are often excluded in HFpEF-related trials. Thus, we aim to evaluate the impact of obesity on major adverse cardiovascular and cerebrovascular events (MACCE) in Hospitalized Geriatric Patients with HFpEF.Methods:We queried the National Inpatient Sample (2019) to identify the geriatric admissions (age ≥65 years) with HFpEF. Comorbidities and outcomes were compared between obese and non-obese patients using relevant ICD-10 codes. Adjusted odds and independent predictors of MACCE with obesity were assessed by multivariable regression controlling for confounders.Results:Of 1743940 geriatric admissions with HFpEF, 430395 (24.7%) were obese [median age 75[70-80], female 63.1%, white 77.1%]. The obese cohort often consisted of relatively younger, female, black patients and had higher rates of obstructive sleep apnea (34.1% vs. 10.9%), diabetes (50.3% vs. 31.3%), hyperlipidemia (62.9% vs. 56.6%), chronic lung disease (48.2% vs 38.4%) and depression (17.3% vs. 13.4%) than non-obese (p

Leggi
Ottobre 2022

Abstract 15611: Impact of Amyloidosis in Patients Undergoing Transcatheter Aortic Valve Replacement: Insights From National Inpatient Sample 2016- 2019

Circulation, Volume 146, Issue Suppl_1, Page A15611-A15611, November 8, 2022. Introduction:Aortic Stenosis (AS) is increasingly recognized as one of the underdiagnosed manifestations of cardiac amyloidosis (CA) and existing literature shows conflicting evidence on the impact of CA on AS.Methods:A retrospective analysis of 2016-2019 NIS was conducted to identify hospitalizations (Age≥18) who underwent TAVR using ICD-10 codes. Existing literature was reviewed to select variables before conducting a univariate screen and balancing between groups with CA vs without CA. Propensity score weights were generated using Doubly robust estimation, and IPTW matching was done. The ATET was calculated by extrapolating propensity weights and using weighted multivariate analysis.Results:Out of 227,200 TAVR, only 245 (1.1%) had a concomitant diagnosis of CA. Hospitalizations with CA had a mean age of 80.49, 71.43% males, 82.98% white, 12.77% black, and others. Analysis total of 3,205 deaths, CA was associated with lower odds of mortality (OR 0.25, p 0.00). Factors associated with increased mortality in TAVR were age, HTN, low household income, elixhauser comorbidity index, mechanical vent >24 hrs, Shock on pressors/device, Pericardial effusion/tamponade, AKI, ESRD on HD, and Acute stroke. Out of 17,590 pacemakers (PPM) implantations, CA was associated with lower odds of getting a PPM (OR 0.13, P 0.00). Factors increasing the risk of getting a PPM were high degree AV block, age, male sex, DM, and ventricular arrhythmias. A total of 4280 acute strokes occurred, and CA was not associated with increased risk following TAVR (OR 0.46, p 0.38). Factors increasing the acute stroke risk after TAVR were age, mechanical vent >24hrs, and anemia. 3460 valve complications occurred, and CA was not associated with increased risk (paravalvular leak, displacement, infection, breakdown, and others) (OR 10.20, p 0.16). A significant risk factor for valve complications after TAVR was the presence of pericardial effusion/tamponade.Conclusions:The presence of CA does not result in poor outcomes in TAVR. Limitations of our study are a small sample, retrospective analysis, and lack of cardiac imaging data. Further studies that eliminate our study’s limitations are required to conclusively evaluate the impact of CA in patients who undergo TAVR.

Leggi
Ottobre 2022

Abstract 289: Temporal Trends In The Incidence And Outcomes Of In-hospital Cardiac Arrest In Patients Hospitalized With Liver Cirrhosis In The Us: Analysis Of The Nationwide Inpatient Sample From 2010-2019

Circulation, Volume 146, Issue Suppl_1, Page A289-A289, November 8, 2022. Introduction:Liver cirrhosis affects an estimated 1 in 400 adults in the US with significant morbidity and mortality. There is limited data on the incidence and outcomes of in-hospital cardiac arrest (IHCA) in liver cirrhosis-related hospitalizations.Methods:Using the appropriate international classification of disease codes, we queried the nationwide inpatient database to identify patients hospitalized with a primary diagnosis of liver cirrhosis who experienced IHCA and underwent cardiopulmonary resuscitation, between 2010 and 2019, We evaluated the temporal trends in the in-hospital outcomes using Cochrane -Armitage test, and factors associated with survival to hospital discharge using logistic regression analysis.Results:7,091,054 weighted liver cirrhosis hospitalizations were identified during the study period. The IHCA incidence rate was 1.4% with a mean age (SD) of 59 years (12) and males were predominantly affected (59.9%). There was an upward trend in IHCA incidence during the study period (1.3% in 2010 to 1.5% in 2019, p < 0.001). The overall survival to hospital discharge rate was 22.2%. No significant change in the mortality trend during the study period. Most of the survivors were discharged to a long-term acute care facility (46.4%) followed by home discharge without the need for home health (24.7%) and short-term acute facilities (12.6%). Factors associated with lower odds of survival to hospital discharge were age > 65 years OR 0.71, 95% CI 0.67 – 0.75, P < 0.001), Black (OR 0.94, 95% CI 0.91 - 0.99, P=0.012) and Hispanic race (OR 0.78, 95% CI 0.74 - 0.81, P < 0.001), and severe comorbidity index (OR 0.63, 95% CI 0.59 - 0.65, P < 0.001).Conclusion:Between 2010 and 2019, we found a slight increase in the IHCA incidence rate among patients hospitalized with liver cirrhosis. Only about one out of 5 patients survived hospital discharge, and this did not change during the study period. Low socioeconomic status and higher comorbidity burden were associated with lower odds of survival. More research is needed to identify strategies that may improve survival outcomes in IHCA among liver cirrhosis patients.

Leggi
Ottobre 2022

Abstract 9885: Possible Risk Factors of In-Hospital Death Among Acute Ischemic Stroke Patients With Atrial Septal Defect; A Study From the 2019 National Inpatient Sample

Circulation, Volume 146, Issue Suppl_1, Page A9885-A9885, November 8, 2022. Introduction:Atrial septal defect (ASD) is one of the most common congenital cardiac defects. It can also allow paradoxical emboli to move into the cerebral vasculature leading to Acute Ischemic Stroke (AIS). As there is a lack of adequate information on the additional risk factors for mortality in ASD patients following AIS, we queried the largest inpatient database in the United States for answers.Methods:Patients with ASD were identified among patients of ages 25 and more admitted with a principal diagnosis of AIS ICD-10 code (I63.x) in 2019 from the National Inpatient Sample(NIS). Various patient characteristics and procedures were also studied. A Multivariate regression model adjusting for several factors allowed our study to further evaluate potential risk factors for mortality among ASD patients.Results:Our study found 551,385 cases of AIS, amongst which 19,670 (3.6%) also had a diagnosis of ASD. ASD patients had a higher risk of requiring mechanical thrombectomy (aOR 1.239, 95% CI 1.167- 1.316, p

Leggi
Ottobre 2022

Abstract 9824: Cardiovascular Complications During Delivery Admissions Associated With Systemic Lupus Erythematosus: A National Inpatient Sample Analysis (2004-2019)

Circulation, Volume 146, Issue Suppl_1, Page A9824-A9824, November 8, 2022. Introduction:Persons with systemic lupus erythematosus (SLE) have an increased risk of obstetric-associated complications. However, data on acute cardiovascular (CV) complications during delivery remain limited.Hypothesis:SLE is associated with increased acute CV complications at the time of delivery.Methods:We used data from the National Inpatient Sample (2004-2019) while utilizing ICD-9 or ICD-10 codes to identify delivery hospitalizations and a diagnosis of SLE.Results:A total of 63,037,442 weighted delivery hospitalizations were identified, of which 0.1% were among persons with SLE (n=77,560). Individuals with SLE were older (median 30 vs. 28 years, p

Leggi
Ottobre 2022

Abstract 13841: Prevalence and Impact of Recreational Cannabis Use on Acute Ischemic Stroke and Related Mortality in Elderly (≥65 Yrs) Peripheral Vascular Disease Patients: A Population-Based Analysis in the US (2016-2019)

Circulation, Volume 146, Issue Suppl_1, Page A13841-A13841, November 8, 2022. Background:Considering preliminary reports suggesting associations between peripheral atherosclerotic disease (cannabis arteritis) and acute ischemic stroke (AIS) with cannabis use disorder (CUD), we sought to study the burden and impact of CUD on AIS risk and outcomes in the elderly with PVD.Methods:The National Inpatient Sample (2016-2019) was used to identify geriatric PVD admissions with vs. without CUD . We compared the burden and risk of AIS admissions with vs. without CUD and subsequent in-hospital mortality using adjusted multivariable regression analyses.Results:Of 5,115,824 total geriatric admissions with PVD (50.6% males, 77.5% white), 21,405 had CUD. The prevalence of DM was lower in the CUD cohort (19.7% vs 33.7%) with comparable rates of HTN and smoking between groups [Table 1]. Concomitant drug use was higher in CUD vs non-CUD cohort. There was AIS period prevalence of 5.2% in CUD vs 4.0% in non-CUD cohorts (p

Leggi
Ottobre 2022

Abstract 11848: Female Gender, Lower Household Income, Non-Medicare Beneficiaries, and Being a Resident of Small-Sized Population Areas are Associated With In-Hospital Mortality Among Patients Living With Human Immunodeficiency Virus (plwh) With Cardiac Arrest: A Retrospective Analysis of National Inpatient Sample Database From 2016 to 2019

Circulation, Volume 146, Issue Suppl_1, Page A11848-A11848, November 8, 2022. Background:Despite major scientific advances in contemporary resuscitation, survival outcome in both in-hospital and out-of-hospital cardiac arrest (CA) patients remain dismal.Objective:How do individuals’ demographic and socioeconomic status, insurance status, and hospital characteristics play a role in survival following CA in patients living with human immunodeficiency virus (PLWH)?Methods:Using the ICD10 codes B20-B24 for HIV and ICD10 code I46 for CA, we queried the national inpatient sample from 2016 to 2019 to identify admission cases of PLWH with CA. Weighted data was analyzed using logistic regression model.Results:Out of 475,910 admissions for PLWH from 2016 to 2019, 4,650 cases had CA. Of these, 3,065 patients died during the course of hospitalization (65.9%). Although mortality rate decreased for both genders over time, the decline was steeper for females (72% in 2016 to 62% in 2019) compared to the males (68% in 2016 to 64% in 2019). Female gender was however associated with an increased odds of death compared to male (OR: 1.2, 95%CI: 1-1.3, p=0.03). Asian or Pacific Islanders were associated with a lower odds ratio for mortality (OR: 0.6, 95%CI: 0.3-1, p=0.04). Additionally, beneficiaries of all the insurance types had higher odds of mortality compared to Medicare beneficiaries (OR between 1.8 and 3). The odds of death decreased with increasing household income (OR between 0.7 and 0.9). Patients admitted to the hospitals of West South Central (OR:1.6) and Pacific Regions (OR:1.7) had a higher mortality rate as had those residing in areas with less than 250,000 populaces (OR: 1.7).Conclusion:Despite declining trend in mortality from CA among hospitalized PLWH, more than 60% of the cases die during their hospital stay. Female gender, lower household income, non-Medicare beneficiaries, and being a resident of smaller size population areas were associated with higher mortality among PLWH hospitalized with CA.

Leggi
Ottobre 2022

Abstract 11920: Positive Hiv Status Increases Length of Stay And Cost of Hospitalization Among Hospitalized Patients With Acute Myocardial Infarction and Heart Failure: An Analysis of National Inpatient Sample 2016 to 2019

Circulation, Volume 146, Issue Suppl_1, Page A11920-A11920, November 8, 2022. Introduction:Due to dramatic advance in the development of highly active antiretroviral therapy, patients living with human immunodeficiency virus (HIV) (PLWH) have gained a near-normal life expectancy. As a result, cardiovascular diseases are now the most common causes of mortality among PLWH.Objectives:We aimed to investigate if HIV positive status affect the outcomes of PLWH hospitalized with acute myocardial infarction (AMI) or heart failure (HF) in the United States.Methods:Using the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), we queried the national inpatient sample database to identify admission cases with AMI or HF between 2016 and 2019. Then, we stratified the AMI and HF cases according to their HIV status. Weighted data was analyzed to compare mortality rate, frequency of home disposition (HD), length of stay, and total hospital charges between HIV positive and HIV negative patients for AMI and HF admission cases.Results:Data pertaining to a total of 28,484,087 admissions was analyzed. Of this, there were 896,702 cases of AMI and 4,154,918 cases of HF. HIV status was positive in 0.24% and 0.32% of AMI and HF patients, respectively.Conclusion:HIV positive status is associated with a longer length of stay and total hospital charged among hospitalized patients with AMI or HF. While PLWH admitted with AMI have a higher mortality rate than HIV negative counterparts, the HIV status does not seem to impact the outcome of HF patients. Additionally, PLWH seem to be more frequently discharged home than HIV negative patients.

Leggi
Ottobre 2022

Abstract 332: Does Concomitant Left Ventricular Unloading Improve Outcomes Of Cardiogenic Shock Managed By Venoarterial Extracorporeal Membrane Oxygenation? Analysis Of National Inpatient Sample Database 2019

Circulation, Volume 146, Issue Suppl_1, Page A332-A332, November 8, 2022. Introduction:Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is often used in patients with cardiogenic shock. However, this strategy can lead to left ventricular (LV) distention, thus compromising myocardial recovery. Therefore, concomitant LV unloading with an Impella device (Abiomed, Danvers, MA) has gained a wide interest to promote LV recovery. We aimed to investigate the in-hospital outcomes of patients with myocardial infarction and cardiogenic shock undergoing VA-ECMO with Impella (ECPELLA) versus VA-ECMO alone.Methods:We conducted a retrospective cohort study using the 2019 National Inpatient Sample Database. Variables were identified using their International Classification of Diseases, 10th revision (ICD-10) codes. Descriptive bivariate and multivariate analyses were performed. A p-value

Leggi
Ottobre 2022

Abstract 12354: Novel Coronavirus Disease 2019 Infection in a Cohort of Patients With Phenotypic Hypertrophic Cardiomyopathy: An Extended Report

Circulation, Volume 146, Issue Suppl_1, Page A12354-A12354, November 8, 2022. Background:Patients with preexisting heart disease suffer more severe outcomes after COVID-19. Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac conditions. We previously reported incidence and outcomes of COVID-19 in HCM in early days of the pandemic. We report results from an expanded and extended HCM cohort.Methods:343 patients with HCM [age 59±17 years, 55% men, 19% NYHA class >1, 63% obstructive, 14% septal reduction therapy, 24% positive family history, 42% selectively genotyped (43% positive for pathogenic mutations), 22% implantable cardioverter-defibrillator (ICD) implants, 27% paroxysmal or permanent atrial fibrillation (AF), 4% AF ablation] were evaluated for COVID-19 from December 2019 to May 2022.Results.Overall, 54 (16%) patients were diagnosed with COVID-19 [56% men, age 55±17 years, 60% obstructive HCM, 5.5% dilated phase HCM, 28% positive family history, 15% genotype positive, 28% with ICD, 17% NYHA class >1, 31% AF]. There were 289 patients without COVID-19 [55% men, age 58±17 years, 63% obstructive HCM, 3% dilated phase HCM, 23% positive family history, 17% genotype positive, 21% with ICD, 19% NYHA class >1, 27% AF]. Patients with COVID-19 were slightly younger (55±17 vs 58±17 years, p 0.046) and more often had dilated phase HCM (5.5% vs 3%) and more often had ICD (28% vs 21%). Eleven (20%) patients with COVID-19 were hospitalized and 1 (2%) died of the disease. Compared to those with mild disease, hospitalized patients with COVID-19 were more often men (82% vs 49%, p 0.04), older (age 59±15 vs. 54±18 years), with obstructive phenotype (73% vs 56%) and with NYHA class >1 symptoms (27% vs 12%). In the studied patient cohort 70% had at least one dose of COVID-19 vaccine. Prior to the infection 63% of patients had no vaccination against SARS-CoV2. Among hospitalized patients 9 (82%) had no vaccination and 2 (18%) were vaccinated and had mild disease.Conclusions.Although Covid-19 infection rate (16%) in studied cohort was slightly lower than in general US population (~25%), hospitalization rate was higher (20% vs 9%) with similar death rates (1-2%). Older man with symptomatic obstructive HCM phenotype noted to have higher risk for hospitalization. Patients with vaccination against SARS-Cov2 tended to require less hospitalization.

Leggi
Ottobre 2022

Abstract 9844: Particulate Matter 2.5, Metropolitan Status, and Heart Failure Outcomes in US Counties: A Nationwide Ecologic Analysis

Circulation, Volume 146, Issue Suppl_1, Page A9844-A9844, November 8, 2022. Epidemiological data on the relationship of particulate matter with a diameter of 2.5 micrometers or less (PM2.5) with heart failure (HF) hospitalizations and mortality in the US are limited. Prior studies have focused on the effects of daily PM2.5exposure and HF hospitalizations in specific geographic locales in the US. Since PM2.5varies by geography, this study aimed to evaluate the relationship between annual ambient PM2.5concentration levels and HF hospitalizations and death at a county level across the US. We performed a cross-sectional analysis of county level HF hospitalizations, mortality, and ambient PM2.5concentration levels across 3135 US counties nationwide with adjustments for county-level demographics, socioeconomic factors, comorbidities, and healthcare-associated behaviors. County PM2.5showed a moderate correlation with HF hospitalization among Medicare beneficiaries (r=0.41) and a weak correlation with the overall county HF mortality (r=0.08) (p-values < 0.01). There was an increase of 0.51 HF Hospitalizations/1,000 Medicare Beneficiaries and 0.74 HF deaths/100,000 residents for every 1 ug/m3increase in annual PM2.5concentration after adjustment for various county level covariates. The relationship between PM2.5concentration levels and both HF hospitalization and mortality remained significant after adjustment for county covariates. Additionally, the association between PM2.5and HF hospitalizations was comparable by metropolitan status of the counties. In conclusion, ambient PM2.5concentration level was associated with higher incidence of HF hospitalizations and deaths at the county level across the 3100 US counties. Future studies to examine policies aimed at reducing ambient particulate matter pollution and downstream effect of improving HF outcomes are warranted.

Leggi
Ottobre 2022

Abstract 11820: A Meta-Analysis of Efficacy and Safety of the New Generation Watchman FLX Device Compared to the Watchman 2.5

Circulation, Volume 146, Issue Suppl_1, Page A11820-A11820, November 8, 2022. Introduction:The first-generation Watchman 2.5 (W2.5) is associated with several limitations, including the difficulty of implantation in complex LAA anatomies, peri device leak, device recapture and device-related thrombosis. The second-generation Watchman FLX (W-FLX) addressed those limitations with proven safety and efficacy of the device.Hypothesis:This meta-analysis compares the safety and efficacy of the Watchman FLX and 2.5 devices.Methods:The meta-analysis was conducted according to PRISMA guidelines. Studies were located through a search strategy utilizing PubMed, Google scholar and MEDLINE from inception to March 20, 2022, with a primary objective to compare the safety and efficacy of the W-FLX and W2.5. After setting inclusion and exclusion criteria, we identified three recently published observational studies.Results:Our analysis included 3 studies comprising 401 patients. New generation W- FLX is associated with less incidence of major-leak compared to the first-generation W 2.5, OR: 0.08 CI (0.06-0.12) P

Leggi
Ottobre 2022